HEALTHNPR HEALTH
Key FDA committee unanimously recommends its first vaccine since 2023
A key FDA committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over. The recommendation marks the committee's first vaccine approval since 2023.
Mentioned
Related Signal
Adjacent reporting
- Key FDA committee unanimously recommends its first vaccine since 2023
- FDA panel recommends mRNA flu vaccine for older adults
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology
- STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
- First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot